remdesivir rdv (Gilead Sciences)
99
Structured Review
Gilead Sciences
remdesivir rdv
Remdesivir Rdv, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15776 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rdv/VEKLURY/pmc13678209-2-0-0
Average 99 stars, based on 15776 article reviews
Remdesivir Rdv, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15776 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rdv/VEKLURY/pmc13678209-2-0-0
Average 99 stars, based on 15776 article reviews
remdesivir rdv - by Bioz Stars,
2026-11
99/100 stars
Images
Related Articles
Injection:Article Title: Article Snippet: .. Grade 3 or Higher AEs by System Organ Class and Preferred Term, Study GS-US-5409012 SOC Preferred Term RDV 3 Days N=279 n (%) PBO 3 Days N=283 n (%) Cardiac disorders (SOC) 2 (0.7%) 2 (0.7%) Angina pectoris 1 (0.4%) 1 (0.4%) Atrial fibrillation 1 (0.4%) 0 (0%) Cardiac failure congestive 1 (0.4%) 0 (0%) Acute myocardial infarction 0 (0%) 1 (0.4%) Gastrointestinal disorders (SOC) 1 (0.4%) 0 (0%) Abdominal pain 1 (0.4%) 0 (0%) Diarrhea 1 (0.4%) 0 (0%) General disorders and administration site conditions (SOC) 7 (1.3%) 5 (1.0%) Fatigue 1 (0.4%) 0 (0%) Injection site thrombosis 1 (0.4%) 0 (0%) Infections and infestations (SOC) 4 (1.4%) 10 (3.5%) COVID-19 pneumonia 0 (0%) 6 (2.1%) Pneumonia 2 (0.7%) 2 (0.7%) COVID-19 1 (0.4%) 2 (0.7%) Tooth infection 1 (0.4%) 0 (0%) Viral myocarditis 1 (0.4%) 0 (0%) Injury, poisoning and procedural complications (SOC) 0 (0%) 1 (0.4%) Lumbar vertebral fracture 0 (0%) 1 (0.4%) Road traffic accident 0 (0%) 1 (0.4%) Investigations (SOC) 1 (0.4%) 1 (0.4%) Alanine aminotransferase increased 1 (0.4%) 0 (0%) Aspartate aminotransferase increased 1 (0.4%) 0 (0%) Fibrin D-dimer increased 0 (0%) 1 (0.4%) Metabolism and nutrition disorders (SOC) 1 (0.4%) 0 (0%) Hypokalemia 1 (0.4%) 0 (0%) Musculoskeletal and connective tissue disorders (SOC) 0 (0%) 1 (0.4%) Musculoskeletal chest pain 0 (0%) 1 (0.4%) Respiratory, thoracic and mediastinal disorders (SOC) 1 (0.4%) 6 (2.1%) Acute respiratory failure 0 (0%) 1 (0.4%) Respiratory failure 1 (0.4%) 1 (0.4%) Dyspnea 0 (0%) 3 (1.1%) Hypoxia 0 (0%) 1 (0.4%) Vascular disorders (SOC) 1 (0.4%) 1 (0.4%) Blood pressure inadequately controlled 1 (0.4%) 0 (0%) Deep venous thrombosis 0 (0%) 1 (0.4%) Total subjects 10 (3.6%) 20 (7.1%) Source: ADAE dataset, Study GS-US-540-9012 Abbreviations: AE, adverse event; PBO, placebo; Infection:Article Title: Article Snippet: .. Grade 3 or Higher AEs by System Organ Class and Preferred Term, Study GS-US-5409012 SOC Preferred Term RDV 3 Days N=279 n (%) PBO 3 Days N=283 n (%) Cardiac disorders (SOC) 2 (0.7%) 2 (0.7%) Angina pectoris 1 (0.4%) 1 (0.4%) Atrial fibrillation 1 (0.4%) 0 (0%) Cardiac failure congestive 1 (0.4%) 0 (0%) Acute myocardial infarction 0 (0%) 1 (0.4%) Gastrointestinal disorders (SOC) 1 (0.4%) 0 (0%) Abdominal pain 1 (0.4%) 0 (0%) Diarrhea 1 (0.4%) 0 (0%) General disorders and administration site conditions (SOC) 7 (1.3%) 5 (1.0%) Fatigue 1 (0.4%) 0 (0%) Injection site thrombosis 1 (0.4%) 0 (0%) Infections and infestations (SOC) 4 (1.4%) 10 (3.5%) COVID-19 pneumonia 0 (0%) 6 (2.1%) Pneumonia 2 (0.7%) 2 (0.7%) COVID-19 1 (0.4%) 2 (0.7%) Tooth infection 1 (0.4%) 0 (0%) Viral myocarditis 1 (0.4%) 0 (0%) Injury, poisoning and procedural complications (SOC) 0 (0%) 1 (0.4%) Lumbar vertebral fracture 0 (0%) 1 (0.4%) Road traffic accident 0 (0%) 1 (0.4%) Investigations (SOC) 1 (0.4%) 1 (0.4%) Alanine aminotransferase increased 1 (0.4%) 0 (0%) Aspartate aminotransferase increased 1 (0.4%) 0 (0%) Fibrin D-dimer increased 0 (0%) 1 (0.4%) Metabolism and nutrition disorders (SOC) 1 (0.4%) 0 (0%) Hypokalemia 1 (0.4%) 0 (0%) Musculoskeletal and connective tissue disorders (SOC) 0 (0%) 1 (0.4%) Musculoskeletal chest pain 0 (0%) 1 (0.4%) Respiratory, thoracic and mediastinal disorders (SOC) 1 (0.4%) 6 (2.1%) Acute respiratory failure 0 (0%) 1 (0.4%) Respiratory failure 1 (0.4%) 1 (0.4%) Dyspnea 0 (0%) 3 (1.1%) Hypoxia 0 (0%) 1 (0.4%) Vascular disorders (SOC) 1 (0.4%) 1 (0.4%) Blood pressure inadequately controlled 1 (0.4%) 0 (0%) Deep venous thrombosis 0 (0%) 1 (0.4%) Total subjects 10 (3.6%) 20 (7.1%) Source: ADAE dataset, Study GS-US-540-9012 Abbreviations: AE, adverse event; PBO, placebo; other:Article Title: Antiviral prodrugs, intermediate-and long-acting formulations and methods Article Snippet: Vero E6 and Huh7.5 cells were propagated in DMEM (Corning) with 10% FBS and Penicillin-Streptomycin (Gibco). Article Title: Article Snippet: Abbreviations: IV, intravenous; PBO, placebo; QD, once daily; Article Title: Remdesivir is active in vitro against tick-borne encephalitis virus and selects for resistance mutations in the viral RNA-dependent RNA polymerase. Article Snippet: RDV (GS-5734), its parent nucleotide (GS-441524), and Mass Spectrometry:Article Title: Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different? Article Snippet: .. GS-441524, ODV, Synthesized:Article Title: Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different? Article Snippet: .. GS-441524, ODV, |